Molbio Diagnostics shares surged 11.7% in morning trade on Friday, September 11, 2026, hitting a fresh record high of ₹1,686.50 on the BSE, marking the stock's strongest performance since its market debut. The company has now surged nearly 109% from its IPO price of ₹807 per share, extending its post-listing gains to around 109% from the IPO price of ₹810. The stock had made a strong market debut on August 17, 2026, listing at a 21.4% premium at ₹980 after the company's ₹940 crore IPO was subscribed more than 70 times during the three-day bidding period. According to CNBC TV18, the IPO received overwhelming demand with 57.32 crore equity shares bid against 81.59 lakh shares on offer, with qualified institutional buyers leading at 186.39 times subscription while non-institutional investors and retail portions were subscribed 49.80 times and 12.96 times respectively. The company had also raised ₹281.5 crore from anchor investors including Goldman Sachs, IFC and BlackRock Global Funds ahead of listing.
Molbio Diagnostics delivered exceptional financial performance in the quarter ended June 2026, posting a consolidated net profit of ₹58.74 crore for Q1 FY27, compared to a net loss of ₹23.74 crore in the corresponding quarter of the previous year. The company's total income surged to ₹411.48 crore in Q1 FY27, compared to ₹100.47 crore in Q1 FY26, as reported by LiveMint. CEO Sriram Natarajan stated that deployment of net issue proceeds is underway across capex for automation and building R&D facility in Bengaluru, with focus on disciplined execution and improving cash flow quality. The company's sales surged 309.57% to ₹408.38 crore in Q1 FY27, demonstrating significant operational improvements and revenue growth. Additionally, the company reported FY26 net profit of ₹166.6 crore, up 14.8% year-on-year, while revenue rose 41.7% to ₹1,445.7 crore. The company turned its operational earnings before interest, tax, depreciation and amortisation (EBITDA) positive on a YoY basis, coming in at ₹101 crore with EBITDA margins improving to 24.6% in the same period.
Truenat test-kit volumes rose sharply to 62.4 lakh units in Q1 FY27 from 7.9 lakh units in the corresponding quarter last year, supporting the company's revenue growth and reinforcing its strong market position. According to LiveMint, the company attributed the improvement to continued growth in Truenat test-kit consumption. Truenat is designed to detect a wide range of infectious diseases with accuracy and speed at the point of care, as per the company's website. The flagship platform is a battery-operated, point-of-care polymerase chain reaction (PCR) system patented in more than 100 countries, enabling decentralised testing and delivering diagnostic results within an hour. The platform supports testing for diseases including tuberculosis, COVID-19, hepatitis B and C, HIV and HPV. The company's growth continues to be led by test-kit consumption across the 12,500+ Truenat devices sold in 90+ countries, with the company offering 43 tests covering 30 diseases.
Molbio Diagnostics' management provided optimistic full-year FY27 guidance, estimating the company's topline growth to be at 25% while the earnings before interest, tax, depreciation and amortisation (EBITDA) margin is expected to range around 24-25% this year. The company management emphasized that the business is not quarterly linear due to public health procurement dynamics, urging investors to set up expectations on an annual basis. Against the backdrop of 60-63% gross margins across its devices and test kits, the medical equipment manufacturer expects to leverage the POC diagnostics market, which is at $30 billion and growing at a 17.9% CAGR. The management also stated that capacity is not a constraint for the firm, with key focus on automation and R&D centres using the proceeds collected from the IPO round. However, geographic mix, foreign exchange, and the company's OptraScan business remain areas of concern for growth in the upcoming period.
Molbio plans to deploy ₹105.5 crore of the fresh issue proceeds towards a research and development facility and Centre of Excellence through subsidiary Bigtec, as reported by CNBC TV18. Another ₹72.2 crore is earmarked for plant, machinery and equipment at its manufacturing facilities in Goa and Visakhapatnam. The company's IPO comprised a ₹200-crore fresh issue and an offer for sale of 91.66 lakh shares. At the current price of ₹1,686.50, the stock has surged 109% from its issue price of ₹807, demonstrating exceptional post-IPO performance in the point-of-care diagnostics sector. The company's market capitalisation stood at ₹17,394 crore as of the trading session on September 10, 2026. The company entered FY27 with meaningful capacity headroom, with FY26 device and test-kit utilisation at 42% and 58% respectively, positioning it for volume-led scale-up without near-term incremental capex.
